BioDuro-Sundia Wins Life Sciences Review Top 10 BPO Award
BioDuro-Sundia Announces Formation of Scientific Advisory Board
BioDuro-Sundia Expands Drug Discovery Capacity and Capability
SHANGHAI--(BUSINESS WIRE)--BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound Library (DEL) technology services in China to help more innovative pharmaceutical companies quickly discover small molecule drugs. X-Chem will leverage its powerful DEL technology platform and large collection of novel, diverse lead- and drug-like small molecule compounds to help customers significantly accelerate the discovery of hits and expand their target range. Combined with BioDuro-Sundia's one-stop drug discovery platform, customers can access world-class discovery technologies and support, covering hit identification and optimization, evaluation of lead and candidate compounds, and quickly advance to preclinical development.
SAN DIEGO--(BUSINESS WIRE)--BioDuro-Sundia, a leading drug discovery, development and commercial services organization backed by Advent International, announced today the appointment of Kent M. Payne, PhD, as Chief Executive Officer. He originally joined BioDuro-Sundia in 2019 as President, Global CMC Solutions.
SAN DIEGO--(BUSINESS WIRE)--BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today it has entered into a definitive agreement to acquire a fully-operational 45,000 ft2 commercial oral solid dose drug product manufacturing facility located at 9601 Jeronimo Road, Irvine, CA. As part of the acquisition, BioDuro-Sundia will employ most of the current staff and provide continuous operations to support production of multiple existing products through a commercial supply agreement. Subject to customary closing conditions, BioDuro-Sundia will assume operations on January 1, 2022.
SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--BioDuro, a global life science research and development organization backed by Advent International (“Advent”), and Sundia, a leading contract research and manufacturing organization, today announced that they have partnered to create one of the largest CRDMOs (contract research, development and manufacturing organizations) with major operations in China and the US. The combined company will operate as BioDuro-Sundia, providing fully integrated drug discovery, development and manufacturing for both API (Active Pharmaceutical Ingredients) and drug products. Advent led a majority investment in Sundia, with Bridgewest Capital as co-investors. Financial terms were not disclosed.